Results for astellas: 30

* Novartis launches first generic version of Prograf * Astellas to challenge FDA over Prograf in court * Astellas shares down 5 pct vs 0.4 pct fall for sector * Analysts see mild falls in...

* Novartis launches first generic version of Prograf * Astellas to challenge FDA over Prograf in court * Astellas shares down 5 pct vs 0.4 pct fall for sector (Recasts) TOKYO, Aug 11 - Swiss...

TOKYO, Aug 11 - Japan's Astellas Pharma Inc said on Tuesday it would challenge the U.S. Food and Drug Administration in court, after the regulator knocked back its request for higher hurdles for generic rivals...

TOKYO, Oct 27 - Japan's Nikkei average lost 1.5 percent for its biggest one-day percentage fall in three weeks on Tuesday as trading houses fell after oil prices slid and Astellas Pharma was hurt by...

TOKYO, Oct 27 - The Nikkei average fell 1.5 percent on Tuesday as Astellas Pharma sank after saying it was terminating development of an arthritis drug, while resource-linked stocks were hurt by lower oil prices....

* Exporters slide after fall on Wall St * Despite solid earnings, economy uncertainty remains -analyst TOKYO, Oct 27 - The Nikkei average fell 1.3 percent on Tuesday as Astellas Pharma sank after saying it...

TOKYO, Aug 13 - Japan's Astellas Pharma said on Thursday a U.S. court has rejected its request for an injunction to prevent the Food and Drug Administration from approving generic products to its top-selling Prograf...

TOKYO, Aug 3 - Astellas Pharma Inc, Japan's second-largest drugmaker, reported on Monday a 4.8 percent drop in April-June recurring profit due to a strong yen. Astellas posted a recurring profit of 69.64 billion yen...

TOKYO, May 13 - Astellas Pharma Inc, Japan's second-largest drugmaker, reported on Wednesday a 4.5 precent decline in annual recurring profit on a stronger yen and forecast a second straight year of lower profits. Astellas,...

BOSTON, March 12 - Gilead Sciences Inc said on Thursday it has stepped in to acquire CV Therapeutics Inc for about $1.4 billion, rescuing the company from a hostile bid from Japan's Astellas Pharma Inc...